George Oral Waring IV, MD, FACS - Up Close With Presbyopia: Novel Emerging Miotic Agents for Aging Eyes

01/16/23 • 12 min

CME in Minutes: Education in Ophthalmology

Please visit answersincme.com/EUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses new treatments for patients with presbyopia. Upon completion of this activity, participants should be better able to:Recognize the unmet therapeutic needs with available presbyopia treatments; Describe the evidence for late-stage emerging miotic agents being developed to treat presbyopia; and Outline strategies to individualize treatment selection for patients with presbyopia.

Previous Episode

Diana V. Do, MD - Bringing Anti-VEGF Therapy into Focus: Comparing and Integrating Treatments for Retinal Vein Occlusion

Please visit answersincme.com/JZM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal vein occlusion (RVO) discusses selecting among and incorporating anti-vascular endothelial growth factor (VEGF) therapy into treatment plans for patients with macular edema (ME) secondary to RVO. Upon completion of this activity, participants should be better able to: Evaluate the benefit-risk profiles of available anti-VEGF treatments for patients with macular edema secondary to RVO; Discuss practical approaches to optimally incorporate anti-VEGF agents into treatment plans for patients with RVO; and Apply strategies to counsel patients on the use of anti-VEGF agents for RVO to optimize patient outcomes.

Next Episode

Christine E. Jones, BMBS, PhD - Preventing Congenital Cytomegalovirus Through Behavioral and Emerging Vaccination Strategies

Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.